Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AVITA MedicalASX:AVH +31.82%59 EV-to-OCF is -10.31 as of Aug. 10, 2026. GuruFocus rates ASX:AVH with a GF Score™ of 59/100 and a GF Value™ of A$2.93 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 853 Medical Devices & Instruments companies, AVITA Medical ranks better than 81.71% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, AVITA Medical's Enterprise Value is A$365.3 Mil.
AVITA Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was A$-35.4 Mil. Therefore, AVITA Medical's EV-to-OCF for today is -10.31.
The historical rank and industry rank for AVITA Medical's EV-to-OCF or its related term are showing as below:
ASX:AVH'
s EV-to-OCF Range Over the Past 10 Years
Min: -46.36 Med: -7.91 Max: -1.47
Current: -11.49
During the past 13 years, the highest EV-to-OCF of AVITA Medical was -1.47. The lowest was -46.36. And the median was -7.91.
ASX:AVH's EV-to-OCF is ranked better than 81.71% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.85
vs ASX:AVH: -11.49
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AVITA Medical's PE Ratio (TTM) for today is calculated as:
AVITA Medical's share price for today is A$2.03.
AVITA Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-0.424.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AVITA Medical EV-to-OCF Related Terms
AVITA Medical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for AVITA Medical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, AVITA Medical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where AVITA Medical's EV-to-OCF falls into.
AVITA Medical's current Enterprise Value is A$365.3 Mil.
AVITA Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-35.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (ASX:AVH) has a EV-to-OCF of -10.31 as of Aug. 10, 2026. According to the industry distribution chart, AVITA Medical ranks #156 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 18.3%.
Is AVITA Medical's EV-to-OCF too high?
AVITA Medical's current EV-to-OCF is -10.31. Based on the distribution chart, AVITA Medical ranks #156 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AVITA Medical has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's EV-to-OCF compare to OWLT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #156 out of 853 companies for EV-to-OCF. This places AVITA Medical in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.85, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current EV-to-OCF is -10.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.93, compared to a current price of A$2.03 — trading 30.7% below its estimated fair value. The current EV-to-OCF is -10.31. AVITA Medical's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current EV-to-OCF is -10.31 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$2.03 is trading 30.7% below its estimated GF Value™ of A$2.93.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for ASX:AVH:
EV-to-OCF: -10.31
GF Value™: A$2.93 vs. price of A$2.03 (30.7% below fair value)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
59GF Score
Get the complete analysis for ASX:AVH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
